Biocause Pharma(SZ:000627) Zheng Quan Zhi Xing·2025-06-20 10:59Core Viewpoint - Tianmao Group is unable to hold the 2024 annual shareholders' meeting within the stipulated timeframe due to incomplete preparation of the annual report, which may lead to significant regulatory consequences [1][2]. Group 1: Reasons for Inability to Hold the Meeting - The company has not completed the preparation of the 2024 annual report, which is required to be disclosed within six months after the end of the previous fiscal year [2]. - The company had previously announced the inability to disclose the 2024 annual report and the Q1 2025 report by the legal deadline [1][2]. Group 2: Solutions and Disclosure Timeline - The company is actively working to complete the necessary reports and will communicate with relevant parties to expedite the process [2]. - Once the reports are finalized, the company will convene a board meeting to review the relevant proposals and subsequently hold the annual shareholders' meeting [2]. Group 3: Impact of Delayed Disclosure - Due to the failure to disclose the 2024 annual report within the legal timeframe, the company's stock has been suspended from trading since May 6, 2025 [2]. - If the company does not disclose the annual report within two months of the stock suspension, it may face delisting risk warnings, and further delays could lead to termination of stock trading [2].